Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101

1 September 2024 (17:48 - 18:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Peter Van Der Meer

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: a nationwide retrospective study using a medical claims database

Doctor H. Abe (Tokyo, JP)

Abstract Slides Video

Presentation thumbnail

Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline

Professor M. Fontana (London, GB)

Abstract Slides Video

Presentation thumbnail

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

Doctor R. Carvalho (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE

Professor O. Lairez (Toulouse, FR)

Abstract Slides Video

Access the full session

Session thumbnail

Advances in amyloidosis

The Event

Event poster

ESC Congress 2024

1 September 2024 17:48 CET

You may be interested in

Congress Session

Advances in amyloidosis

Congress Presentation

Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101

Congress Session

Therapeutic advances in amyloid cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources